Approval of ‘Invega Trinza,’ Janssen’s schizophrenia, is approaching
A schizophrenia therapy to administer 4 times a year is soon to be commercialized.
According to the industry concerned on the 30th, a Janssen Korea’s long-acting injection which was applied for approval at the end of the last year, ‘Invega Trinza,’ is expected to acquire approval from the Minis...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
